Thiotepa-based Conditioning for Blood Cancers
This study is testing a new way to prepare patients for an allogeneic stem cell transplant (alloSCT) for certain blood cancers like Acute Lymphocytic Leukemia (ALL), Acute Myeloid Leukemia (AML), and Myelodysplastic Syndrome (MDS). It uses a combination of chemotherapy drugs: Thiotepa, Busulfan, and Fludarabine, followed by a reduced dose of post-transplant cyclophosphamide (PTCy). The goal is to improve how well the transplant works by reducing side effects like graft-versus-host disease (GVHD) and preventing the cancer from coming back. You might be able to join if you are 18 to 70 years old and considered a good candidate for a stem cell transplant. The study plans to enroll 48 participants and will measure success by how many patients are free from GVHD and relapse one year after transplant. The current recruitment status is unclear.
- Study design
- This is an interventional study, meaning participants will receive specific treatments. It plans to enroll 48 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed to measure GVHD-free, relapse-free survival (GRFS) at 1 year after the transplant.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Thiotepa-based Conditioning Regimen With De-escalated Post-graft Cyclophosphamide for Allogeneic Stem Cell Transplantation in Hematologic Malignancies
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Sawa M Ito, MD · PRINCIPAL_INVESTIGATOR · UPMC Hillman Cancer Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- GVHD-free, relapse-free survival (GRFS)At 1 year
Graft Versus Host Disease (GVHD)-free, relapse-free survival (GRFS) is defined by survival without a qualifying event including Death, Relapse of primary disease, Grade III-IV acute graft-versus-host disease (GVHD), graded via MAGIC criteria, Chronic moderate or severe GVHD requiring systemic immunosuppression, graded via NIH consensus criteria.